Ranbaxy Halts Shipments of APIs from Two Plants
As reported by the Economic Times of India, India's largest generic drug maker, Ranbaxy Laboratories, has "voluntarily" suspended all shipments of drug ingredients produced at two of its India-based plants - one in Dewas and one in Toansa - to review processes and controls.
An earlier report from the Economic Times stated that production was halted following a visit from Japanese drug maker Daiichi Sankyo Co., which aquired a controlling share of Ranbaxy in 2008.
This suspension will affect supplies in key markets in Europe and India. All India-based Ranbaxy factories — Paonta Sahib (Himachal Pradesh), Dewas (Madhya Pradesh), Mohali (Punjab) and Toansa (Punjab) — are already barred from exporting drugs to the U.S.
Read the Economic Times release